Sundar Jagannath, MBBS

Sundar Jagannath, MBBS, explores how minimal residual disease could redefine what it means to achieve a "cure" in multiple myeloma.

Sundar Jagannath, MBBS, discusses the potential use of linvoseltamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.

Sundar Jagannath, MBBS, discusses outcomes with linvoseltamab vs teclistamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.

Sundar Jagannath, MBBS, discusses the FDA’s ODAC Meeting on safety considerations with ide-cel in multiple myeloma.

Sundar Jagannath, MBBS, discusses takeaways from the FDA’s ODAC consensus on safety considerations with cilta-cel in relapsed/refractory multiple myeloma.

Sundar Jagannath, MBBS, discusses the safety of linvoseltamab in relapsed/refractory multiple myeloma.

Sundar Jagannath, MBBS, discusses CAR T-cell therapy considerations prior to initiation in the management of multiple myeloma.

Sundar Jagannath, MBBS, discusses the patient population evaluated in the LINKER-MM1 trial of linvoseltamab in relapsed/refractory multiple myeloma.

Sundar Jagannath, discusses the potential role for linvoseltamab in relapsed/refractory multiple myeloma.

Sundar Jagannath, MBBS, discusses the mechanism of action and tolerability of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Sundar Jagannath, MBBS, discusses the FDA approval of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.